Qiming Venture Partners-Backed Belief BioMed Announces Approval of China's First Hemophilia B Gene Therapy Drug Xinjining®
As China's first independently developed gene therapy for hemophilia B, Xinjiuning® will offer patients a completely new treatment option, with the potential to free them from a lifetime of frequent intravenous injections and help them return to a life without constraints.








